CLAIMS

1. Use of a composition comprising IGFBP7 in the manufacture of a medicament for the adjunct treatment of severe or cerebral malaria.

2. The use according to claim 1, wherein the medicament inhibits IRBC-endothelial cytoadherence.

3. The use according to any one of claims 1 or 2, wherein the composition further comprises a Von Willebrand Factor (VWF) and/or a thrombospondin-1 (TSP-1).

4. The use according to claim 3, wherein the amount of VWF present in the composition is between 0.125 and 0.5 IU/ml.

5. The use according to claim 3, wherein the amount of the TSP-1 present in the composition is at least 10 ng/ml.

6. The use according to any one of the preceding claims, wherein the amount of IGFBP7 present in the composition is about at least 100 ng/ml.

7. The use according to any one of the preceding claims, wherein the IGFBP7 is used as together with one or more other anti-malarial drugs.

8. The use according to claim 7, wherein the anti-malarial drugs are selected from the group comprising artemisinin or artesunate and its derivatives, chloroquine, mefloquine pyrimethamine, sulfadoxine, amodiaquine, quinine/quinidine, halofantrine, atovaquone, proguanil and doxycycline.